This technology is a topical hydrogel/cream containing genetically engineered yeast that continuously secretes human CXCL12 and EGF to speed up wound healing and reduce complications.
The natural healing process can be time-consuming, and chronic wounds such as diabetic ulcers, burns, and other topical diseases can be life-threatening if left untreated. Without a proper dressing, they heal slowly and unevenly, increasing the risk of infection, re-injury, and other complications. Epidermal growth factor (EGF) is recognized as an excellent wound healing agent due to its ability to stimulate skin cell growth, proliferation, and differentiation. However, current EGF dressings are not sustained and long-lasting, requiring frequent re-application and a lengthy healing process.
This technology leverages topical application of engineered yeast strains to secrete two wound-healing factors: epidermal growth factor (EGF) and chemokine CXCL12 (SDF-1). Embedded in hydrogel or cream, the yeast survives long enough to provide continuous, physiologic-level release of both proteins through the critical inflammatory and proliferative phases of wound repair. Animal studies demonstrate that the yeast hydrogel closes wounds faster than blank dressings, purified growth-factor hydrogels, and single-strain yeast formulations, demonstrating synergistic and sustained activity without the cost or instability of purified biologics.
This technology has been validated in vivo using mouse models.
Patent Pending (US20240285701)
IR CU22252
Licensing Contact: Joan Martinez